Completed PHASE2 INTERVENTIONAL 2-arm NCT03769935

Maintenance Therapy for Small-cell Lung Cancer

Preliminary Study of Maintenance Therapy for Patients With Extensive Stage of Small-cell Lung Cancer

Sponsor: Qingdao Central Hospital

Interventions cis Platinum, etoposide, S1

Updated 5 times since 2019 Last updated: Mar 27, 2023 Started: Jan 1, 2017 Primary completion: Jan 1, 2022 Completion: Jul 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Progression Free Survival and is currently completed. Qingdao Central Hospital leads this study, which shows 5 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Apr 2023 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qingdao Central Hospital

Data source: Qingdao Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China